ES2797091T3 - Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario - Google Patents
Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario Download PDFInfo
- Publication number
- ES2797091T3 ES2797091T3 ES17704548T ES17704548T ES2797091T3 ES 2797091 T3 ES2797091 T3 ES 2797091T3 ES 17704548 T ES17704548 T ES 17704548T ES 17704548 T ES17704548 T ES 17704548T ES 2797091 T3 ES2797091 T3 ES 2797091T3
- Authority
- ES
- Spain
- Prior art keywords
- propan
- methoxy
- pyrrolidin
- ylamino
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16155123 | 2016-02-10 | ||
| EP16186188 | 2016-08-29 | ||
| PCT/IB2017/050743 WO2017118965A1 (en) | 2016-02-10 | 2017-02-10 | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2797091T3 true ES2797091T3 (es) | 2020-12-01 |
Family
ID=58016749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17704548T Active ES2797091T3 (es) | 2016-02-10 | 2017-02-10 | Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario |
Country Status (25)
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2547270T3 (es) | 2008-07-17 | 2015-10-05 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP2723740A1 (en) * | 2011-06-27 | 2014-04-30 | Novartis AG | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| WO2015162584A1 (en) * | 2014-04-24 | 2015-10-29 | Novartis Ag | Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide |
-
2017
- 2017-02-10 US US16/075,066 patent/US20190038628A1/en not_active Abandoned
- 2017-02-10 DK DK17704548.1T patent/DK3413894T3/da active
- 2017-02-10 KR KR1020187022701A patent/KR20180108651A/ko not_active Application Discontinuation
- 2017-02-10 JP JP2018542236A patent/JP7132123B2/ja active Active
- 2017-02-10 PL PL17704548T patent/PL3413894T3/pl unknown
- 2017-02-10 EP EP17704548.1A patent/EP3413894B1/en active Active
- 2017-02-10 LT LTEP17704548.1T patent/LT3413894T/lt unknown
- 2017-02-10 ES ES17704548T patent/ES2797091T3/es active Active
- 2017-02-10 HU HUE17704548A patent/HUE050632T2/hu unknown
- 2017-02-10 RU RU2018132042A patent/RU2749731C2/ru active
- 2017-02-10 RS RS20200668A patent/RS60477B1/sr unknown
- 2017-02-10 PT PT177045481T patent/PT3413894T/pt unknown
- 2017-02-10 SI SI201730288T patent/SI3413894T1/sl unknown
- 2017-02-10 WO PCT/IB2017/050743 patent/WO2017118965A1/en active Application Filing
- 2017-02-10 MX MX2018009758A patent/MX2018009758A/es active IP Right Grant
- 2017-02-10 CN CN201780010050.XA patent/CN108601786B/zh active Active
- 2017-02-10 BR BR112018015272-2A patent/BR112018015272A2/pt not_active Application Discontinuation
- 2017-02-10 AU AU2017204936A patent/AU2017204936B2/en active Active
- 2017-02-10 CA CA3011205A patent/CA3011205A1/en active Pending
- 2017-02-10 EP EP20162199.2A patent/EP3695840A1/en not_active Withdrawn
-
2018
- 2018-06-26 IL IL260274A patent/IL260274A/en unknown
- 2018-07-10 CL CL2018001871A patent/CL2018001871A1/es unknown
- 2018-07-11 PH PH12018501490A patent/PH12018501490A1/en unknown
- 2018-12-21 HK HK18116434.0A patent/HK1257288A1/zh unknown
-
2020
- 2020-06-08 HR HRP20200916TT patent/HRP20200916T1/hr unknown
- 2020-06-10 CY CY20201100526T patent/CY1122989T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3695840A1 (en) | 2020-08-19 |
| JP7132123B2 (ja) | 2022-09-06 |
| PH12018501490A1 (en) | 2019-03-25 |
| US20190038628A1 (en) | 2019-02-07 |
| RS60477B1 (sr) | 2020-08-31 |
| KR20180108651A (ko) | 2018-10-04 |
| LT3413894T (lt) | 2020-07-10 |
| CY1122989T1 (el) | 2021-10-29 |
| RU2749731C2 (ru) | 2021-06-16 |
| AU2017204936B2 (en) | 2019-06-27 |
| CN108601786B (zh) | 2021-11-02 |
| WO2017118965A1 (en) | 2017-07-13 |
| HUE050632T2 (hu) | 2020-12-28 |
| DK3413894T3 (da) | 2020-06-15 |
| CL2018001871A1 (es) | 2018-11-23 |
| RU2018132042A3 (US20030204162A1-20031030-M00001.png) | 2020-05-15 |
| HK1257288A1 (zh) | 2019-10-18 |
| PT3413894T (pt) | 2020-06-16 |
| MX2018009758A (es) | 2018-09-11 |
| EP3413894B1 (en) | 2020-03-11 |
| BR112018015272A2 (pt) | 2018-12-18 |
| CA3011205A1 (en) | 2017-07-13 |
| PL3413894T3 (pl) | 2020-10-05 |
| IL260274A (en) | 2018-07-31 |
| AU2017204936A1 (en) | 2018-07-19 |
| RU2018132042A (ru) | 2020-03-10 |
| EP3413894A1 (en) | 2018-12-19 |
| SI3413894T1 (sl) | 2020-09-30 |
| CN108601786A (zh) | 2018-09-28 |
| HRP20200916T1 (hr) | 2020-09-18 |
| JP2019508413A (ja) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramirez et al. | GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations | |
| Khan et al. | PD-L1hi B cells are critical regulators of humoral immunity | |
| Vedhara et al. | Human psychoneuroimmunology | |
| Voskuhl et al. | T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes | |
| Peng et al. | Increased toll-like receptors activity and TLR ligands in patients with autoimmune thyroid diseases | |
| Fransen et al. | Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin‐17 | |
| Stoye et al. | Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice | |
| KR20100063060A (ko) | Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물 | |
| Ma et al. | A novel combination of astilbin and low-dose methotrexate respectively targeting A2AAR and its ligand adenosine for the treatment of collagen-induced arthritis | |
| Maier‐Moore et al. | Interleukin‐6 Deficiency Corrects Nephritis, Lymphocyte Abnormalities, and Secondary Sjögren's Syndrome Features in Lupus‐Prone Sle1. Yaa Mice | |
| Schubert et al. | Oral zinc aspartate treats experimental autoimmune encephalomyelitis | |
| KR20110066193A (ko) | Ｂ-헬퍼 ｔ 세포를 감소시켜 자가면역 질환을 치료하는 방법 | |
| ES2939534T3 (es) | Activación moduladora de inflamasomas de células supresoras derivadas de mieloides para tratar EICH | |
| ES2797091T3 (es) | Uso de inhibidores de la actividad o de la función de la PI3K para el tratamiento del síndrome de Sjögren primario | |
| Knuplez et al. | The anti‐parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice | |
| Erlandsson et al. | IGF1R signalling is a guardian of self-tolerance restricting autoantibody production | |
| Inoue et al. | Bone marrow stromal cell antigen-1 deficiency protects from acute kidney injury | |
| Zhao et al. | Blockade of OX40/OX40L signaling using anti-OX40L delays disease progression in murine lupus | |
| Saleh | Pro-inflammatory mediators in arthritic pain and disease | |
| Agrez et al. | An immunomodulating peptide with potential to suppress tumour growth and autoimmunity | |
| Alotaibi | Lipopolysaccharide Inhibits Interleukin–13-induced Chemokine (CC motif) Ligand 26 in Human Airway Epithelial Cells: Possible Role in Eosinophil Chemotaxis in Allergic Asthma | |
| Griesenauer | ST2/MYD88 signaling is a therapeutic target alleviating murine acute graft-versus-host disease sparing T regulatory cell function | |
| Berg | A Small Molecule Inhibitor of ITK and RLK | |
| Abou-Raya et al. | THU0166 Rebamipide in the treatment of xerostomia in sjægren’s syndrome: Randomized placebo-controlled study | |
| Osborne | Integrin Mediated Cellular Adhesion May Alter the Cytokine Profile in Acute Lymphoblastic Leukemia |